ClinicalTrials.gg
CompletedNCT00583128Updated Jun 18, 2014

Safety and Efficacy of AST-120 in Patients With Non-Constipating Irritable Bowel Syndrome

A Phase 2 interventional study of AST-120 and Celphere® CP-305 in Irritable Bowel Syndrome, sponsored by Ocera Therapeutics. Completed at 17 sites in 2 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-06-18.

Sponsored by Ocera Therapeutics (part of Keenova Therapeutics plc) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 344 studies in Irritable Bowel Syndrome with a site in United States — 45 open to participants now, 49 under way, 3 of them phase 3. Irritable Bowel Syndrome · United States.

Enrollment
100th of 287
117 · median 61
Started
2007
with 10 others
Phase 2
80 of 344
8 open now
Registered
36th of 344
by date

Among the 344 studies in Irritable Bowel Syndrome with a site in United States, this one is the 100th largest by enrollment of the 287 interventional ones that give a count, is one of 11 that started in 2007, is one of 80 in phase 2, and was the 36th registered.

Irritable Bowel Syndrome

1,119 studies on the registry are indexed under Irritable Bowel Syndrome; 210 are open to participants now.

Browse Irritable Bowel Syndrome studies →

Open to participants now

45 of the 344 studies in Irritable Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:

40 more — sign in →

All 45 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 129 Irritable Bowel Syndrome studies recruiting now, 34 (26%) set no upper age limit and 85 (66%) stop at 75 or younger; 19 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 344 studies in Irritable Bowel Syndrome with a site in United States, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the safety and effectiveness of the experimental drug AST-120 in treating patients with non-constipating IBS. The study will test whether or not patients receiving AST-120 experience at least a 50% reduction in the number of days with abdominal pain compared to placebo.

Read the detailed description

Patients experiencing non-constipating IBS will be randomized to one of two arms in the study: the experimental drug AST-120 or placebo. Patients will take 2g of AST-120 or placebo three times per day for eight weeks. After the 8 week course, patients will receive an additional 8 weeks single blind treatment, after a one week washout period.

The experimental drug AST-120 is composed of black, odorless spherical carbon particles in 2g sachets (aluminum foil pouches). The placebo consists of microcrystalline cellulose spheres, Celphere CP-305 stained to match the appearance of AST-120, in 2g sachets (aluminum foil pouches). Both AST-120 and placebo are oral (taken by mouth) preparations. Both are tasteless. To take the product, patients will tear open the sachet, drop the contents directly on their tongue and wash it down with 8 ounces of water.

Patients will be expected to participate in up to 10 visits, approximately three by telephone and the remainder of visits are in-clinic. At these visits, patients will undergo a number of tests including: hematology panel, lactose intolerance testing, physical exams, pregnancy tests, evaluations based on the following scales: The Bristol Stool Scale, IBS Severity Scale, IBS Quality of Life, SCL-90R.

Provided the patient has been stable for eight weeks prior to their baseline visit, they will be allowed to take the following medications: drugs that inhibit gastric secretion (histamine blockers, proton pump inhibitors), benzodiazepines and Imidazopyridines (short acting, nonbenzodiazepine hypnotics) for sleep (dose must be consistent with the use of a sleep agent) aspirin at a cardiovascular prophylactic dose (75-150 mg/day) and paracetamol. Antidepressants for non-IBS symptoms are allowed. Loperamide will be permitted as a rescue for diarrhea only when patients are experiencing at least 3 liquid or soft stools in one day. However, Loperamide is prohibited during the two week screening period.

Patients will not be allowed to take the following medications whilst on trial and these therapies must have been discontinued by at least two weeks prior to their baseline visit: probiotics, neuroleptics, antidepressants for IBS symptoms, daytime tranquilizers, prokinetics, spasmolytics, analgesics, other investigational agents and any over-the-counter medications.

Patient will be required to keep a diary during the study

03

Conditions studied

  • Irritable Bowel Syndrome

Keywords

  • IBS
  • Irritable Bowel Syndrome
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Body weight ≥ 40 kg;
  • Recurrent abdominal pain or discomfort for three or more days per month for the last three months which meets Rome III criteria for non-constipating IBS;
  • Patients on a stable diet for at least eight weeks;
  • Patients ≥ 50 years of age with a negative screening colonoscopy in the last five years;
  • Able and willing to comply with all protocol procedures for the planned duration of the study;
  • Able and willing to understand, sign and date an document, and authorize access to protected health information,
  • Females must be , surgically incapable of bearing children, or practicing a reliable method of (intrauterine devices, spermicide and barrier) (Hormonal contraceptives are NOT regarded as adequate for the purpose of this trial.) Partner/spouse sterility may also qualify at the Investigator's discretion. Females of must have a negative urine pregnancy test at baseline.

Exclusion criteria

Exclusion Criteria:

  • Constipating IBS;
  • History of untreated lactose intolerance;
  • History of colonic or major abdominal surgery (colectomy, for example);
  • Active (untreated) Thyroid disease;
  • Current diagnosis of major depression or psychosis;
  • Known positive stool cultures for Clostridium difficile or other pathogens;
  • Any condition necessitating the administration of analgesics (except paracetamol), probiotics, neuroleptics, antidepressants for IBS symptoms, daytime tranquilizers, prokinetics or spasmolytic medications;
  • Poor tolerability of venipuncture or lack of adequate venous access for required blood sampling;
  • Other major physical or major psychiatric illness within the last six months that in the opinion of the investigator would affect the patient's ability to complete the trial;
  • Uncontrolled systemic disease such as diabetes;
  • Patients undergoing chemotherapy for the treatment of cancer;
  • Known or to any component of the test product (study drugs) or diagnostics used;
  • Participation in another study within eight (8) weeks prior to the study;
  • Unable to attend all visits required by the protocol;
  • Female patients must be excluded if they are pregnant, breast feeding, or planning to become pregnant during the study.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    1

    AST-120, 2 gram sachets

    Drug: AST-120

  • Placebo comparator
    2

    Celphere® CP-305, stained to match appearance of AST-120, in 2g sachets

    Drug: Celphere® CP-305

Interventions

  • DrugAST-120

    Drug pages: AST 120 · Charcoal

    oral, sachet, 2 grams three times daily for 8 weeks

  • DrugCelphere® CP-305

    oral, placebo, sachet, 2 grams three times daily for 8 weeks

06

What researchers measure

Primary outcomes

  1. Percent of patients who achieve at least a 50% reduction in the number of days with abdominal pain during the final 2 weeks of the double-blind treatment course.

    Time frame: Eight weeks

  2. Safety endpoint is adverse events (AEs) deemed possibly, probably, or definitely related to treatment with investigational product during the double-blind treatment course.

    Time frame: 8 weeks

Secondary outcomes

  1. Percent change in the IBS QOL score.

    Time frame: Eight weeks

  2. Percent change in HADS score.

    Time frame: 8 weeks

  3. Percent change in Bristol Scale score.

    Time frame: 8 weeks

  4. Percent change in individual items in the IBS Symptom Severity questionnaire.

    Time frame: 8 weeks

  5. Durability of effect after the first eight weeks of treatment.

    Time frame: 8 weeks

  6. Change in clinical laboratory tests from Baseline to Week 8 and to Week 18.

    Time frame: 8 weeks

  7. Any adverse event occurring after Week 8.

    Time frame: 8 weeks

  8. Physical examinations, vital signs (blood pressure, heart rate, respiration and temperature).

    Time frame: 8 weeks

07

Study locations

17 sites
  • Clinical Research Associates
    Huntsville, Alabama 35801, United States
  • Northern California Research
    Sacramento, California 95821, United States
  • Medical Center for Clinical Research
    San Diego, California 92108, United States
  • Madeleine DuPree, MD
    Boynton Beach, Florida 33436, United States
  • Michael Epstein, MD
    Annapolis, Maryland 21401, United States
  • Chevy Chase Clinical Research
    Chevy Chase, Maryland 20815, United States
  • Long Island Gastrointestinal Research Group
    Great Neck, New York 11023, United States
  • LeBauer Research Associates
    Greensboro, North Carolina 27403, United States
  • Peters Medical Research, LLC
    High Point, North Carolina 27262, United States
  • Ohio Gastroenterology and Liver Institute
    Cincinnatti, Ohio 45219, United States
  • Oklahoma Foundation for Digestive Disease
    Oklahoma City, Oklahoma 73104, United States
  • Breco Research LTD
    Houston, Texas 77024, United States
  • Wisconsin Center for Advanced Research
    Milwaukee, Wisconsin 53215, United States
  • AZ St. Lucas Assebroek
    Assebroek, 8310, Belgium
  • Zuid-Oost Limburg Campus St. Jan
    Genk, 3600, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • UCL St. Luc
    Woluwe, 1200, Belgium
08

References and documents

Publications

  • Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006 Apr;130(5):1377-90. doi: 10.1053/j.gastro.2006.03.008. No abstract available. PubMed 16678553 ↗
  • Schuster MM. Defining and diagnosing irritable bowel syndrome. Am J Manag Care. 2001 Jul;7(8 Suppl):S246-51. PubMed 11474909 ↗
  • Tack J, Broekaert D, Fischler B, Van Oudenhove L, Gevers AM, Janssens J. A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome. Gut. 2006 Aug;55(8):1095-103. doi: 10.1136/gut.2005.077503. Epub 2006 Jan 9. PubMed 16401691 ↗
  • Wood JD. Histamine, mast cells, and the enteric nervous system in the irritable bowel syndrome, enteritis, and food allergies. Gut. 2006 Apr;55(4):445-7. doi: 10.1136/gut.2005.079046. PubMed 16531524 ↗
  • Tack JF, Miner PB Jr, Fischer L, Harris MS. Randomised clinical trial: the safety and efficacy of AST-120 in non-constipating irritable bowel syndrome - a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011 Oct;34(8):868-77. doi: 10.1111/j.1365-2036.2011.04818.x. Epub 2011 Aug 24. PubMed 21883322 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of May 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 20, 2007
First posted
Dec 31, 2007
Start
Aug 2007
Primary completionActual
May 2010
CompletionActual
Jun 2010
Results delay requested
Jul 26, 2013
Last update
Jun 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00583128
Lead sponsor
Ocera Therapeutics
Responsible party
Sponsor
First posted
Dec 31, 2007
Start date
Aug 2007
Primary completion
May 2010
Completion
Jun 2010
Last update
Jun 18, 2014

Study contacts

Jan Tack, MD
principal investigator · University of Leuven, Department of Gastroenterology

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: AST 120 · Charcoal

Start the discussion